Vanda Pharmaceuticals (VNDA) Stock Price, Quote & News

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for prev...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States

JenningsB Sep. 4 at 2:32 PM

$VNDA Just checking this after seeing two different Vanda Nereus commercials during today's USA-China FIBA game on TNT.

0 · Reply

TomMac64 Sep. 4 at 1:22 PM

$VNDA I have another fact when they put NEURUS on car #47 cause it was the first FDA motion sickness approval in 47 years I thought that was bigtime stupid …. how about NEURUS on the best car possible with a real chance to win races ?!

0 · Reply

TomMac64 Sep. 4 at 12:17 PM

$VNDA FACTS that’s what matters ; Revenue $250M , very little debt (about zero) how come nobody mentions that , market cap about $300M , several approved drugs , Zero R/S after 20yrs public , cash until 4th qrt 27’ , Bysanti patent (which I think is huge ) 2044 , GLP-1 data before EOY these are tangible items not speculation cause I’m a know it all !

0 · Reply

TomMac64 Sep. 4 at 12:05 PM

$VNDA Why do people like you come on this board and say something like this “it’s about to get crushed” the thing is expert anyone who has traded for sometime knows this is a scam market designed to steal money from anyone possible WE KNOW …. It could go to $1.47 but I’m not gonna post it cause everyone ALREADY KNOWS THAT …. and it could get BO at 9am this morning drrrrrrr ?????????????

1 · Reply

Its_Only_Money_369 Sep. 4 at 12:52 AM

$VNDA It won’t just get rejected, it’s about to get crushed. Back to 4.35 in six trading days. Either this rips in the morning or I’m taking a little off the table and adding through the buy now pay later strategy. It is in a squeeze, unfortunately, in my experience, it’s about to squeeze the wrong way. Seems as if several charts are moving in the exact opposite direction of what would be expected lately though. Let’s just hope common sense prevails here. This should be 5X on pipeline and speculation. So many things are about to give in the foundation of the world economy. People are completely blinded by what is flashing before their eyes and chase what they are fed rather than use common sense and ask the questions that matter. This will be a safe space, no debt + growth while financialsare on the brink from rising yields and exchange rates becoming too far off balance. Rates will go up and we will print trillions to buy back debt.

1 · Reply

johnle66 Sep. 3 at 7:17 PM

$VNDA Can't help myself, just purchased another 5200

1 · Reply

TomMac64 Sep. 3 at 6:10 PM

$VNDA How much did BlackRock invest ?

0 · Reply

pablo4 Sep. 3 at 6:00 PM

$VNDA given VNDA's cash runway through 2027 but not beyond, my guess is these upcoming conferences are being read as plans by VNDA to be poised to raise money. I'm bullish; I'm long and unconcerned over a capital raise given all the catalysts and deep pipeline, especially the chance to break into the GLP-1 market with a trial success there.....BUT I'm a realist and not hiding my head in the sand. The timing of these conferences may well bode to plans to raise capital. If mgt was savvy (no great evidence of it being "business" savvy at all), it would raise capital amid some good news and not in this current malaise. JMO

3 · Reply

MS1974 Sep. 3 at 4:55 PM

$VNDA Could anything be worse than this stock?

2 · Reply

Trendrebel Sep. 3 at 9:59 AM

$VNDA Gosh ! This share is predictable. Someone has to update the algos ! Anyway - now we are just below MA50, and we will go up and test it ( blue line ). Then it will ( probably ) be rejected to the downside, like 80% of the times, it touched from below. If I´m wrong, we´ll have a great chance of gap close ( 7,40 ). Cross fingers ! 🤞

0 · Reply

Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences

2026-08-24T11:10:07.000Z - 13 days ago

Vanda awarded Orphan Designation in Europe for treatment of GPP

Aug 24, 2026, 7:00 AM EDT - 13 days ago

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Aug 22, 2026, 3:16 PM EDT - 15 days ago

NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.

2026-08-10T12:39:12.000Z - 27 days ago

Vanda Pharmaceuticals price target lowered to $12 from $17 at B. Riley

2026-08-10T10:10:14.000Z - 27 days ago

Vanda Pharmaceuticals price target lowered to $20 from $21 at H.C. Wainwright

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vanda Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vanda Pharmaceuticals Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 4 weeks ago

Vanda Pharmaceuticals Quarterly report: Q2 2026

2026-08-05T20:06:21.000Z - 4 weeks ago

Vanda Pharmaceuticals reports Q2 EPS ($1.04) vs. (46c) last year

2026-08-05T20:05:57.000Z - 4 weeks ago

Vanda Pharmaceuticals sees FY26 revenue $240M-$290M, consensus $262.1M

Aug 5, 2026, 4:01 PM EDT - 4 weeks ago

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Jul 29, 2026, 4:31 PM EDT - 5 weeks ago

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

2026-07-16T20:35:23.000Z - 7 weeks ago

Vanda announces EMA positive opinion for orphan drug designation of Imsidolimab

Jul 16, 2026, 4:30 PM EDT - 7 weeks ago

Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

Jul 15, 2026, 4:30 PM EDT - 7 weeks ago

NEREUS™ Powers Forward: Sponsors No. 47 IndyCar Entry, Celebrating 47 Years Since Last New U.S. Motion Sickness Treatment

Jul 10, 2026, 4:30 PM EDT - 1 month ago

Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit

2026-07-07T20:50:18.000Z - 2 months ago

Vanda Pharmaceuticals announces Rare Pediatric Disease Designation for VCA-894A

Jul 7, 2026, 4:30 PM EDT - 2 months ago

Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S

Jun 4, 2026, 9:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Transcript: AGM 2026

2026-05-27T11:24:38.000Z - 3 months ago

Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan

May 27, 2026, 7:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis

May 19, 2026, 2:00 PM EDT - 3 months ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 18, 2026, 7:00 AM EDT - 3 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

2026-05-11T10:50:03.000Z - 3 months ago

Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright

May 7, 2026, 6:44 PM EDT - 4 months ago

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

2026-05-07T01:52:21.000Z - 4 months ago

Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year

2026-05-07T01:50:55.000Z - 4 months ago

Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M

May 6, 2026, 4:30 PM EDT - 4 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Vanda Pharmaceuticals Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 months ago

Vanda Pharmaceuticals Quarterly report: Q1 2026

May 6, 2026, 4:01 PM EDT - 4 months ago

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

2026-05-04T12:46:08.000Z - 4 months ago

Vanda Pharmaceuticals announces U.S. commercial availability of Nereus

May 4, 2026, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

2026-05-01T20:40:19.000Z - 4 months ago

Vanda Pharmaceuticals announces commercial availability for Nereus

Apr 29, 2026, 4:30 PM EDT - 4 months ago

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 28, 2026, 7:12 PM EDT - 4 months ago

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

ANAB

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 4 months ago

Vanda Pharmaceuticals Proxy statement: Proxy filing

Apr 22, 2026, 5:13 PM EDT - 4 months ago

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

2026-04-09T15:10:15.000Z - 5 months ago

Vanda calls on FDA to remove proposal extending drug review timelines

Apr 9, 2026, 11:02 AM EDT - 5 months ago

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

2026-04-08T20:50:15.000Z - 5 months ago

Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting

Apr 8, 2026, 4:44 PM EDT - 5 months ago

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Mar 19, 2026, 4:34 PM EDT - 5 months ago

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Mar 11, 2026, 2:15 PM EDT - 5 months ago

Vanda Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 6, 2026, 6:00 AM EST - 6 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

2026-03-05T11:11:50.000Z - 6 months ago

Vanda Pharmaceuticals initiated with a Buy at Truist

Mar 3, 2026, 8:01 AM EST - 6 months ago

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

Feb 26, 2026, 4:35 PM EST - 6 months ago

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

Feb 25, 2026, 7:18 AM EST - 6 months ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Feb 23, 2026, 10:28 AM EST - 6 months ago

Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

Feb 20, 2026, 6:03 PM EST - 6 months ago

US FDA approves Vanda's psychiatric drug

Feb 20, 2026, 5:59 PM EST - 6 months ago

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Feb 12, 2026, 7:00 AM EST - 6 months ago

Vanda Pharmaceuticals Registration statement: Registration Filing

Feb 11, 2026, 4:30 PM EST - 6 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Vanda Pharmaceuticals Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Vanda Pharmaceuticals Earnings release: Q4 2025

Feb 11, 2026, 4:01 PM EST - 6 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 4, 2026, 6:01 PM EST - 7 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 15, 2026, 12:00 PM EST - 7 months ago

Vanda Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 7:00 AM EST - 7 months ago

Vanda Pharmaceuticals Slides: Corporate presentation

Jan 8, 2026, 9:31 AM EST - 8 months ago

Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 7:00 AM EST - 8 months ago

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Dec 31, 2025, 10:57 AM EST - 8 months ago

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Dec 30, 2025, 6:30 PM EST - 8 months ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:13 PM EST - 8 months ago

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

Dec 15, 2025, 7:00 AM EST - 8 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Dec 11, 2025, 5:02 PM EST - 8 months ago

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:21 PM EST - 9 months ago

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 28, 2025, 7:00 AM EST - 9 months ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 17, 2025, 6:37 PM EST - 9 months ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 12, 2025, 4:40 PM EST - 9 months ago

Vanda Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 9, 2025, 6:00 PM EST - 10 months ago

Vanda Pharmaceuticals Slides: Corporate Presentation

Nov 5, 2025, 5:00 PM EST - 10 months ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals Earnings release: Q3 2025

Oct 29, 2025, 4:01 PM EDT - 10 months ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 10 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 11 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 11 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Sep 9, 2025, 8:30 AM EDT - 12 months ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 1 year ago

Vanda Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 5:23 PM EDT - 1 year ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 1 year ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 1 year ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

JenningsB Sep. 4 at 2:32 PM

$VNDA Just checking this after seeing two different Vanda Nereus commercials during today's USA-China FIBA game on TNT.

0 · Reply

TomMac64 Sep. 4 at 1:22 PM

0 · Reply

TomMac64 Sep. 4 at 12:17 PM

0 · Reply

TomMac64 Sep. 4 at 12:05 PM

1 · Reply

Its_Only_Money_369 Sep. 4 at 12:52 AM

1 · Reply

johnle66 Sep. 3 at 7:17 PM

$VNDA Can't help myself, just purchased another 5200

1 · Reply

TomMac64 Sep. 3 at 6:10 PM

$VNDA How much did BlackRock invest ?

0 · Reply

pablo4 Sep. 3 at 6:00 PM

3 · Reply

MS1974 Sep. 3 at 4:55 PM

$VNDA Could anything be worse than this stock?

2 · Reply

Trendrebel Sep. 3 at 9:59 AM

0 · Reply

MikeBob15 Sep. 3 at 2:32 AM

$VNDA Took this as part of a bounce play. Their products and pipeline seem rather Tepid with immense competition. However, their GLP 1 side effects Drug for Vomiting and Nauseousnes has serious potential. In America alone 11 percent or roughly 30 million adults are taking GLP 1s. Approximately, 20 percent of people taking them experience vomiting. That would be 6 million people just in the US. The number of people taking GLP 1s likely hasn't peaked by any means. Anything related to them is red hot right now... I see that drug as showing the most future potential and promise for them. They have enough money where they could make a deal for another asset for their portfolio. That or a buyback. Im sure they need all that cash with everything they have going on.

0 · Reply

jacckkmm Sep. 2 at 10:15 PM

$VNDA https://finance.yahoo.com/healthcare/articles/vanda-pharmaceuticals-announces-participation-september-203000244.html Looks like a lot of PR/for them coming up ! Getting the “Who we are” moment out there … love it

0 · Reply

TomMac64 Sep. 2 at 9:19 PM

$VNDA And you will be rewarded for your smarts …. way to go !

0 · Reply

johnle66 Sep. 2 at 8:12 PM

$VNDA 3 years I have been watching and holding this stock, I feel BO coming soon. I didn't sell at $9.50 and I am not selling now, I am the definition of a long.

0 · Reply

TomMac64 Sep. 2 at 5:42 PM

$VNDA 20 yrs public , 60M shares , Zero R/S how many approved drugs …. Bysanti patent 44’ and big GLP-1 data on the horizon as well as another approval how can you not hold this gem thru this scamming price action ?

0 · Reply

Kri81 Sep. 2 at 5:32 PM

$VNDA BOO IM

0 · Reply

TomMac64 Sep. 2 at 4:39 PM

$VNDA Big Pharma could care less about their spending problems !

0 · Reply

TomMac64 Sep. 2 at 4:25 PM

$VNDA. Heading into several catalysts !

0 · Reply

Kri81 Sep. 2 at 4:09 PM

$VNDA Needs to break 16 before we hit 17

1 · Reply

chuckL4 Sep. 2 at 3:04 PM

$VNDA Since management has a spending problem, it will be difficult to gain any real momentum in the stock until the results of the GLP trial is completed in Q4. If positive the stock price should increase dramatically and I would expect takeover prospects [LLY knows VNDA well] to heat up considerably. Until then we wait.

1 · Reply

sck2 Sep. 2 at 2:50 PM

$VNDA nope, that's not the point ... ✅

1 · Reply

sck2 Sep. 2 at 2:46 PM

$VNDA moving with the sector* you say ... I would agree with you if we were trading at $15 but at $5+ ... come on ... joke!!!

3 · Reply

Market Cap	328.31M
Revenue (ttm)	216.11M
Net Income (ttm)	-220.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.02%
Debt to Equity Ratio	0.00

Volume	589,400
Avg Vol	904,926
Day's Range	N/A - N/A
Shares Out	60.46M
Stochastic %K	52%
Beta	0.64
Analysts	Strong Sell
Price Target	$12.19